bms-986089
Recombinant proteinexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02145234)
Timeline
Indications
Mechanism of action
- DystrophinSupplementation
DMD supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297914 ↗
Also known as
- bms-986089
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281495 | Phase 2 | Nov 24, 2025 | Biohaven Pharmaceuticals Inc. |
| NCT05337553 | Phase 3 | Jul 6, 2022 | Biohaven Pharmaceuticals Inc. |
| NCT03039686 | Phase 2/Phase 3 (Phase 3) | Jun 2, 2017 | Bristol-Myers Squibb |
| NCT03100630 | Phase 1 | May 1, 2017 | Bristol-Myers Squibb |
| NCT02515669 | Phase 1/Phase 2 (Phase 2) | Dec 2, 2015 | Bristol-Myers Squibb |
| NCT02145234 | Phase 1 | Jun 1, 2014 | Bristol-Myers Squibb |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 3 | 2014 |
| Biohaven Pharmaceuticals Inc. | For profit | 2 | 2 | 2 | 2022 |
2 organizations
Page 1 / 1